Skip to content

Comparative study of therapeutic effects of diacerein and chondroitin sulfate in adult Kashin-Beck disease patients

Accurate screening of drugs for oral treatment of kashin-beck disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039600
Enrollment
Unknown
Registered
2020-11-02
Start date
2019-06-15
Completion date
Unknown
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kashin-Beck disease

Interventions

chondroitin sulfate:Take Chondroitin sulfate
Glucosamine:Take Glucosamine
diacerein:take diacerein

Sponsors

Chinese Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: According to the "diagnosis of Kashin Beck disease" standard (WS / t207-2010) (grade I: multiple and symmetrical thickening of finger joints, thickening of other limbs joints, limitation of flexion and extension, pain, mild muscle atrophy, metaphysis or bone end; grade II: on the basis of grade I, symptoms and signs worsened, and short finger (toe) deformity appeared).

Exclusion criteria

Exclusion criteria: Individuals with other joint diseases, such as joint inflammation, metabolic bone diseases, neoplasia, osteoporosis, etc. or coexisting conditions such as a history of diabetes mellitus, stroke, emaciation, long-term use of drugs and cardiovascular, gastrointestinal, kidney, liver, respiratory diseases, or those who declined to participate in the study were excluded.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;

Secondary

MeasureTime frame
Frequency of affected joints;Joint dysfunction index evaluation scale;

Countries

China

Contacts

Public ContactYu J
6yujun@126.com+86 13100881735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026